Rezetecán

Rezetecán (SHR9265) is a topoisomerase I inhibitor. In addition, Rezetecán can be used to synthesize Trastuzumab rezetecan, an antineoplastic agent. Rezetecán can be used as a cytotoxic payload (ADC Cytotoxin) in antibody-drug conjugates (ADCs) [1][2].

Product Specifications

Product Name Alternative

SHR9265

UNSPSC

12352005

Target

ADC Payload; Topoisomerase

Type

Reference compound

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/rezetec-n.html

Purity

99.60

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)[C@@H](N)CSC(C1)C(N(CCCCCC(NCC(NCC(N[C@@H](CC2=CC=CC=C2)C(NCC(NCO[C@H](C3CC3)C(N[C@H]4CCC5=C6C4=C(CN7C(C(COC([C@@]8(CC)O)=O)=C8C=C79)=O)C9=NC6=CC(F)=C5C)=O)=O)=O)=O)=O)=O)C1=O)=O

Molecular Formula

C58H67FN10O15S

Molecular Weight

1195.27

References & Citations

[1]WHO Drug Information, Vol. 36, No. 2, 2022. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.|[2]Loganzo F, et al. Mechanisms of resistance to antibody–drug conjugates[J]. Molecular cancer therapeutics, 2016, 15 (12) : 2825-2834.